With regard to the use of antimalarial drugs in the Canadian Armed Forces, for each year from 2003 to March 9, 2017: (a) which pharmaceutical companies were awarded contracts for antimalarial drugs administered; and (b) what was the unit cost for (i) 250 mg mefloquine, (ii) 100 mg doxycycline, (iii) 250/100 mg atovaquone-proguanil, (iv) 500 mg chloroquine phosphate (300 mg base)?
In the House of Commons on September 18th, 2017. See this statement in context.